Asia Pacific Alopecia Treatment Market, 2016 - 2024

Asia Pacific Alopecia Treatment Market, 2016 - 2024
Persistence Market Research
Asia Pacific Alopecia Treatment Market to
Reach US$ 2,655.9 Mn by 2024: Persistence
Market Research
Persistence Market Research
1
Asia Pacific Alopecia Treatment Market, 2016 - 2024
According to the latest market report published by Persistence Market Research, titled “Asia
Pacific Alopecia Treatment Market: Industry Analysis and Forecast (2016–2024)”,
revenue from the Asia Pacific alopecia treatment market is expected to expand at a CAGR of
6.6% during the forecast period 2016 - 2024.
In the report, the Asia-Pacific alopecia treatment market is analyzed on the basis of, type of
alopecia, treatment type, and end user. On the basis of the type of alopecia, the overall
market has been segmented into alopecia areata, alopecia totalis, and alopecia universalis.
Topical drugs (creams, oils, lotions, gels, shampoos, and foam), oral drugs, injectable
(platelet rich plasma therapy, steroid, and injectable fillers), hair transplant services and
low-level laser therapy form the basis of treatment type. By end user segment, the market
has been segmented into hospitals, dermatology and trichology clinics, home care settings,
and aesthetic clinics. In the overall market, oral solid dosage formulations are expected to
witness increased acceptance owing to ease of consumption by patients in Asia Pacific.
Accordingly, oral drugs segment is anticipated to witness an increase in value from US$
556.6 Mn in 2016 to US$ 1,005.1 Mn by the end of 2024.
Request Sample of this Report:
http://www.persistencemarketresearch.com/samples/11077
Rising global demand for effective hair loss treatment medications especially oral drugs is
the prime driver of the market. Oral hair loss treatment drugs are gaining popularity as they
help in maintaining patient-safety through reduced number of medicine dosages, but with
increased drug efficacy. However, changing lifestyle along with the increase in stress level
among working class population, cosmeceutical drug manufacturers focusing on expanding
their hair treatment and scalp treatment product line, and cytokine therapy gaining
momentum for alopecia treatment are other factors that expected to fuel the market growth
for alopecia treatment market over the forecast period.
Patent expiry of major blockbuster drugs resulting in market exclusivity for some brands and
various side effects associated with the hair loss treatments is expected to hamper the
overall market growth. Some of the side effects such as allergies, depression, and chances
of permanent sexual dysfunctions. Other market deterrents include the limited efficacy of
Persistence Market Research
2
Asia Pacific Alopecia Treatment Market, 2016 - 2024
the hair loss treatment drugs and lack of reimbursement facilities for hair loss treatments
services, such as laser treatments.
To View TOC: http://www.persistencemarketresearch.com/market-research/asia-pacificalopecia-treatment-market/toc
Based on countries, the market has been divided into China, Japan, Australia & New
Zealand, Malaysia, Singapore, India, Vietnam, Philippines and Rest of Asia-Pacific. Developed
pharmaceuticals markets such as the China and Japan are expected to emerge as the main
sourcing markets.
This report assesses trends by type of alopecia, treatment type, end user, and countries; to
offer analytical insights about the potential demand emerging for particular alopecia
treatments in specific regions. China is estimated to dominate the alopecia treatment
market accounting for maximum revenue share of the overall market by end of 2016. By
2024 end, China and Japan markets are expected to account for over three-fifth share of the
Asia Pacific alopecia treatment market revenue. In terms of market share by value, China is
estimated to retain its dominant position, registering a CAGR of 7.1% over the forecast
period.
Browse Full Report: http://www.persistencemarketresearch.com/market-research/asiapacific-alopecia-treatment-market.asp
Some key companies covered in this report include Teva Pharmaceutical Industries Ltd.,
Merck & Co., Inc., Johnson & Johnson, Inc., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Cellmid
Ltd., The Himalaya Drug Company, Taisho Pharmaceutical Holdings Co., Ltd, Shiseido Co.,
Ltd., and Zhangguang 101 Science & Technology Co., Ltd. These companies are primarily
focused on enhancing their product portfolio through research and development and the
introduction of innovative and cost-effective advanced manufacturing procedures in order to
gain higher market share and to strengthen their respective positions in the Asia Pacific
market.
To Buy Full Report: http://www.persistencemarketresearch.com/checkout/11077
Persistence Market Research
3
Asia Pacific Alopecia Treatment Market, 2016 - 2024
Market Bytes:
Alopecia is a prevalent autoimmune disorder, resulting in loss of hair all over the body,
predominantly on the scalp. It usually starts with one or smaller round patches on the scalp
(alopecia areata) and progresses to total scalp hair loss (alopecia totalis), or complete body
hair loss (alopecia universalis). Alopecia universalis is the least prevalent autoimmune
disorder, affecting less than 5% of total population with alopecia. The management of
extensive alopecia is challenging and sometimes patients may not respond to therapy. The
most common prescribed medication for hair regrowth includes anti-inflammatory
medications including topical and intraleisonal corticosteroid injections. Topical 2% and 5%
minoxidil solution, and oral finasteride (such as propecia manufactured by Merck and Co.
Inc.) is also recommended in treatment of hair loss. The Asia Pacific market for alopecia
treatment has been segmented based on treatment type as topical drugs, oral drugs,
injectable, hair transplant services, and low level laser therapy. The market has also been
segmented by type of alopecia, by end user, and by country.
The Asia Pacific alopecia treatment market is estimated to be valued at US$ 2,665.9 Mn by
2024 end, with various markets registering significant CAGRs during the forecast period.
Growth of the alopecia treatment market is mainly driven by increasing demand for hair loss
treatment drugs with enhanced effectiveness and minimal side effects. For example, in
recent years cytokine therapy as well regenerative cell therapy is gaining popularity for
treatment of various types of alopecia. Treatment with cytokine therapy possess extended
ability in hair regrowth resulting in hair follicle cells to get differenced and proliferated while
controlling hair growth cycle. Additionally, combination therapies have also demonstrated its
clinical efficacy in treatment of alopecia. Combination therapeutics is currently the widest
adopted treatment for hair loss management across the Asia Pacific region. Various
combination of drugs are being tried by physicians for increasing the effectiveness of
treatment of all kinds of alopecia. However, patent expiry of many blockbuster drugs and
side effects associated with the available hair loss treatment therapies are expected to
hamper the overall market growth hair loss treatments.
Increasing penetration of advanced hair loss treatment therapies, such as stem cell therapy
and increased focus on providing hair loss solutions (with both functional and active
Persistence Market Research
4
Asia Pacific Alopecia Treatment Market, 2016 - 2024
ingredients) with multifunctional effects is set to define the market landscape of the hair loss
industry over the forecast period.
Based on type of alopecia, the market has been segmented into alopecia areata, alopecia
totalis, and alopecia universalis. In Asia Pacific, prevalence of alopecia areata has been
growing significantly over the years attributed to increasing prevalence of various
dermatology related skin disorders. In terms of value, alopecia areata segment is estimated
to account for close to one-third of the total market share by 2024 end. The segment is
expected to gain market attractiveness throughout the forecast period.
Based on treatment type, the market has been segmented into topical drugs, oral drugs,
injectable, hair transplant services, and low level laser therapy. Topical drugs includes
creams, gels, lotions, shampoos, and foam, while the injectable treatment type segment
includes platelet rich plasma therapy, steroids, and injectable fillers. Propecia, an oral
medicines (generic is finasteride) is currently the only FDA approved medicine in treatment
of alopecia. Limited clinical efficacy demonstrated by such treatments would hamper market
share and revenue growth of established products over the forecast period.
Based on end user, the Asia Pacific alopecia treatment market has been segmented into
hospitals, dermatology and trichology clinics, home care settings, and aesthetic clinics.
Dermatology and trichology clinics segment is the highest revenue contributor to the Asia
Pacific alopecia treatment market followed by home care settings and end user segments.
Over the counter distribution and high level of e-Commerce adoption is expected to lead to
increased adoption of topical hair loss treatments in home care settings. The segment is
expected to be valued at US$ 656.9 Mn by 2024 end, registering a significant CAGR over the
forecast period.
The Asia Pacific alopecia treatment market has been segmented into nine major countries
namely China, Japan, Australia & New Zealand, Malaysia, Singapore, India, Vietnam,
Philippines and Rest of Asia Pacific. In terms of value, China is estimated to be the dominant
market for alopecia treatment, accounting US$ 961.3 Mn of the total alopecia treatment
market value by 2024 end. India is estimated to emerge as the fastest growing market
among all the emerging regions, while revenue from the market in Vietnam is expected to
Persistence Market Research
5
Asia Pacific Alopecia Treatment Market, 2016 - 2024
expand at a healthy CAGR of 5.2% over the forecast period despite the ongoing economic
downturn in the region.
Some of the key players covered in the alopecia treatment market report are Teva
Pharmaceutical Industries Ltd., Merck & Co., Inc., Johnson & Johnson, Inc., Dr. Reddy’s
Laboratories Ltd., Cipla Ltd., Cellmid Ltd., The Himalaya Drug Company, Taisho
Pharmaceutical Holdings Co., Ltd, Shiseido Co., Ltd., and Zhangguang 101 Science &
Technology Co., Ltd. The report is enriched through identification of company-specific
strategies related to various hair loss treatments, research and development, market
consolidation initiatives, and analyses of the various market player’s specific strengths,
weaknesses, opportunities, and threats.
PMR for Journalist: http://www.persistencemarketresearch.com/page/journalistresources.asp
About Us:
Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated
research, custom research, and consulting services. PMR boasts market research expertise across the
Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages,
Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The
company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data
that precisely corresponds to clients’ business needs.
Contact Us:
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353
Email: [email protected]
[email protected]
Web: http://www.persistencemarketresearch.com
Persistence Market Research
6